BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 28492873)

  • 1. Sphingosine-1-Phosphate Mediates Fibrosis in Orbital Fibroblasts in Graves' Orbitopathy.
    Ko J; Chae MK; Lee JH; Lee EJ; Yoon JS
    Invest Ophthalmol Vis Sci; 2017 May; 58(5):2544-2553. PubMed ID: 28492873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Sphingosine-1-Phosphate in Adipogenesis of Graves' Orbitopathy.
    Kim SE; Lee JH; Chae MK; Lee EJ; Yoon JS
    Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):301-11. PubMed ID: 26830367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifibrotic effects of quercetin in primary orbital fibroblasts and orbital fat tissue cultures of Graves' orbitopathy.
    Yoon JS; Chae MK; Jang SY; Lee SY; Lee EJ
    Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5921-9. PubMed ID: 22871832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sphingosine-1-phosphate is involved in inflammatory reactions in patients with Graves' orbitopathy.
    Seo Y; Chae MK; Han SA; Lee EJ; Lee JH; Yoon JS
    Inflamm Res; 2017 Jun; 66(6):535-545. PubMed ID: 28364200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of microRNA-146a in regulation of fibrosis in orbital fibroblasts from patients with Graves' orbitopathy.
    Jang SY; Park SJ; Chae MK; Lee JH; Lee EJ; Yoon JS
    Br J Ophthalmol; 2018 Mar; 102(3):407-414. PubMed ID: 29101123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD40 Enhances Sphingolipids in Orbital Fibroblasts: Potential Role of Sphingosine-1-Phosphate in Inflammatory T-Cell Migration in Graves' Orbitopathy.
    Plöhn S; Edelmann B; Japtok L; He X; Hose M; Hansen W; Schuchman EH; Eckstein A; Berchner-Pfannschmidt U
    Invest Ophthalmol Vis Sci; 2018 Nov; 59(13):5391-5397. PubMed ID: 30452592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of tanshinone IIA in an in vitro model of Graves' orbitopathy.
    Rhiu S; Chae MK; Lee EJ; Lee JB; Yoon JS
    Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):5900-10. PubMed ID: 25159204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of miR-146a in the Regulation of Inflammation in an In Vitro Model of Graves' Orbitopathy.
    Jang SY; Chae MK; Lee JH; Lee EJ; Yoon JS
    Invest Ophthalmol Vis Sci; 2016 Aug; 57(10):4027-34. PubMed ID: 27494344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Pirfenidone on TGF-β1-Induced Myofibroblast Differentiation and Extracellular Matrix Homeostasis of Human Orbital Fibroblasts in Graves' Ophthalmopathy.
    Wu SB; Hou TY; Kau HC; Tsai CC
    Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein tyrosine phosphatase 1B as a therapeutic target for Graves' orbitopathy in an in vitro model.
    Byeon HJ; Kim JY; Ko J; Lee EJ; Don K; Yoon JS
    PLoS One; 2020; 15(8):e0237015. PubMed ID: 32760098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential Therapeutic Role of Bone Morphogenic Protein 7 (BMP7) in the Pathogenesis of Graves' Orbitopathy.
    Kim BY; Choi SH; Kim JY; Ko J; Yook JI; Kim HS; Lee EJ; Kikkawa DO; Yoon JS
    Invest Ophthalmol Vis Sci; 2022 Jun; 63(6):7. PubMed ID: 35671049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between sphingosine-1-phosphate-induced signal transduction via mitogen-activated protein kinase pathways and keloid formation.
    Jung SH; Song YK; Chung H; Ko HM; Lee SH; Jo DI; Kim B; Lee DH; Kim SH
    Arch Dermatol Res; 2019 Nov; 311(9):711-719. PubMed ID: 31385019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yes-Associated Protein Mediates the Transition from Inflammation to Fibrosis in Graves' Orbitopathy.
    Ko J; Kim YJ; Choi SH; Lee CS; Yoon JS
    Thyroid; 2023 Dec; 33(12):1465-1475. PubMed ID: 37800725
    [No Abstract]   [Full Text] [Related]  

  • 14. Essential role of connective tissue growth factor (CTGF) in transforming growth factor-β1 (TGF-β1)-induced myofibroblast transdifferentiation from Graves' orbital fibroblasts.
    Tsai CC; Wu SB; Kau HC; Wei YH
    Sci Rep; 2018 May; 8(1):7276. PubMed ID: 29739987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of Connective Tissue Growth Factor (CTGF) Expression in Orbital Fibroblasts from Patients with Graves' Ophthalmopathy.
    Tsai CC; Wu SB; Chang PC; Wei YH
    PLoS One; 2015; 10(11):e0143514. PubMed ID: 26599235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and Smad-independent signaling.
    Sobel K; Menyhart K; Killer N; Renault B; Bauer Y; Studer R; Steiner B; Bolli MH; Nayler O; Gatfield J
    J Biol Chem; 2013 May; 288(21):14839-51. PubMed ID: 23589284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of fibroblast growth factor 10 with the fibrotic and inflammatory pathogenesis of Graves' orbitopathy.
    Jang SY; Choi SH; Kikkawa D; Lee EJ; Yoon JS
    PLoS One; 2021; 16(8):e0255344. PubMed ID: 34383782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor-β-sphingosine kinase 1/S1P signaling upregulates microRNA-21 to promote fibrosis in renal tubular epithelial cells.
    Liu X; Hong Q; Wang Z; Yu Y; Zou X; Xu L
    Exp Biol Med (Maywood); 2016 Feb; 241(3):265-72. PubMed ID: 26376826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone Deacetylase 4 Controls Extracellular Matrix Production in Orbital Fibroblasts from Graves' Ophthalmopathy Patients.
    Ekronarongchai S; Palaga T; Saonanon P; Pruksakorn V; Hirankarn N; van Hagen PM; Dik WA; Virakul S
    Thyroid; 2021 Oct; 31(10):1566-1576. PubMed ID: 34235979
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibitory Effect of Idelalisib, a Selective Phosphatidylinositol 3-Kinase δ Inhibitor, on Adipogenesis in an In Vitro Model of Graves' Orbitopathy.
    Ko J; Kim JY; Lee EJ; Yoon JS
    Invest Ophthalmol Vis Sci; 2018 Sep; 59(11):4477-4485. PubMed ID: 30193323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.